Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia

Author： Rubinstein Ethan   Corey G Ralph   Stryjewski Martin E   Kanafani Zeina A  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.17, 2011-12, pp. : 2737-2750

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Telavancin: a novel lipoglycopeptide for serious Gram-positive infections

By Laohavaleeson Somvadee   Kuti Joseph L   Nicolau David P  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 3, 2007-03 ,pp. : 347-357

Informa Healthcare

Access to resources Recommend Favorite

Novel antibacterial agents for the treatment of serious Gram-positive infections

By Abbanat Darren   Macielag Mark   Bush Karen  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 3, 2003-03 ,pp. : 379-399

Informa Healthcare

Access to resources Recommend Favorite

Telavancin ATTAINs benefit in hospital-acquired pneumonia

By  

Inpharma, Vol. 1, Iss. 1664, 2008-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Newer developments in the treatment of Gram-positive infections

By Koomanachai Pornpan   Crandon Jared L   Nicolau David P  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 17, 2009-12 ,pp. : 2829-2843

Informa Healthcare

Access to resources Recommend Favorite

Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections

By Eisenstein Barry I  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 9, 2004-09 ,pp. : 1159-1169

Informa Healthcare

Access to resources Recommend Favorite